ALDH2 and neoplasm: By knocking out ALDH2 in ALDH2-normal A375 cells, we demonstrated that ALDH2 downregulation enhanced AcAH and ROS production, MAPK/ERK activation, tumor growth, and resistance to targeted therapy, underscoring its clinical relevance and association with poorer patient survival.